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Reduction of Recurrent Ischemia With Abciximab During
Continuous ECG-Ischemia Monitoring in Patients
With Unstable Angina Refractory to
Standard Treatment (CAPTURE)
Peter Klootwijk, MD; Simon Meij, MS; Rein Melkert, MS;
Timo Lenderink, MD; Maarten L. Simoons, MD
Background—In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with
refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours
preceding coronary intervention through 1 hour after intervention. To investigate the incidence of recurrent ischemia and
the ischemic burden, a subset of 332 patients (26%) underwent continuous vector-derived 12-lead
ECG-ischemia monitoring.
Methods and Results—Patients were monitored from start of treatment through 6 hours after coronary intervention.
Ischemic episodes were detected in 31 (18%) of the 169 abciximab and in 37 (23%) of the 163 placebo patients (NS).
Only 9 (5%) of abciximab versus 22 (14%) of placebo patients had $2 ST episodes (P,0.01). In patients with ischemia,
abciximab significantly reduced total ischemic burden (P,0.02), which was calculated alternatively as the total duration
of ST episodes per patient, the area under the curve of the ST vector magnitude during episodes, or the sum of the areas
under the curves of 12 leads during episodes. Twenty-one patients (6%) suffered a myocardial infarction (MI) (18) or
died (3) within 5 days of treatment. The presence of asymptomatic and symptomatic ST episodes during the monitoring
period preceding coronary intervention was associated with an increased relative risk of these events of 3.2 (95% CI 1.4,
7.4) and 4.1 (95% CI 1.4, 12.2), respectively.
Conclusions—Recurrent ischemia predicts MI or death within 5 days of follow-up. Treatment with abciximab is associated
with a reduction of frequent ischemia and a reduction of total ischemic burden in patients with refractory unstable
angina. As such, patients with ischemia derive particularly high benefit from abciximab. (Circulation.
1998;98:1358-1364.)
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Computer-assisted continuous ST monitoring is a practi-cal, noninvasive tool for detection and quantification of
myocardial ischemia and recognition of myocardial infarction
(MI) in patients with unstable coronary syndromes.1–4 From a
recent study using computer-assisted continuous ST monitor-
ing in patients with unstable angina, it appeared that up to
60% of patients exhibited at least one 1 episode of ischemia
within the first 24 hours of admission, and only 23% of
patients remained free of ST episodes during an ST monitor-
ing period of 48 hours.4 In unstable angina patients, myocar-
dial ischemia may develop as the result of platelet aggrega-
tion and intracoronary thrombosis at the site of plaque
fissuring or rupture.5,6 Recurrent ischemia detected during
computer-assisted continuous ST monitoring may thus spe-
cifically reflect episodes of platelet aggregation in these
patients.
Abciximab, an inhibitor of the platelet glycoprotein IIb/IIIa
receptor, has been shown to reduce the rate of complications
associated with concurrent PTCA and during follow-up in
patients with clinical or angiographic features indicating
increased procedural risk.7–9 In the CAPTURE study (c7E3
Fab Anti Platelet Therapy in Unstable REfractory angina),
which was designed to assess the value of treatment with
abciximab in patients with refractory unstable angina during
18 to 24 hours preceding PTCA, a major reduction of death,
MI, or urgent intervention within 30 days after enrollment
was obtained from 15.9% of the placebo group, compared
with 11.3% in patients receiving abciximab.10
ECG-ischemia monitoring was conducted as a substudy
within CAPTURE. The primary objective of this substudy
was to investigate the effects of abciximab compared with
placebo on the incidence and severity of recurrent ischemia
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during continuous vector-derived 12-lead ECG monitoring in
patients with unstable angina refractory to standard drug
treatment who were scheduled for PTCA within 24 hours.
These effects were studied before, during, and up to 6 hours
after PTCA. A secondary objective was to assess the rela-
tionship of recurrent ischemia during continuous vector-
derived 12-lead ECG monitoring with the clinical events as
defined in the main CAPTURE study.
Methods
Study Organization and Patient Selection
This ECG-ischemia monitoring study was conducted as a substudy
of CAPTURE. Patients were recruited by 13 hospitals (those that had
the availability of ECG-monitoring equipment) of the 69 participat-
ing in CAPTURE. All patients underwent continuous ECG monitor-
ing using a vector-derived 12-lead ECG recording system (MIDA
1000, Ortivus Medical), as described below.
For an extensive description of the CAPTURE study design,
patient selection, and inclusion and exclusion criteria, we refer to the
recently reported CAPTURE main trial.10 In brief, patients were
eligible for the CAPTURE study if they had refractory unstable
angina, defined as: chest pain at rest with concomitant ECG
abnormalities compatible with myocardial ischemia (ST-segment
depression, ST-segment elevation, or abnormal T waves) and 1 or
more episodes of either typical chest pain and/or ECG abnormalities
compatible with myocardial ischemia during therapy with intrave-
nous heparin and nitroglycerin, which started $2 hours previously.
The most recent episode of ischemia should have occurred within 48
hours preceding enrollment, corresponding to Braunwald class III
acute unstable angina.11,12 All patients had undergone coronary
angiography and had significant coronary artery disease with a
culprit lesion suitable for PTCA. Patients were enrolled within 24
hours after diagnostic angiography. Before enrollment, all patients
gave informed consent.
The exclusion criteria applied for the CAPTURE main trial also
applied for the present ECG-ischemia monitoring substudy. For the
latter, patients with ECG abnormalities, such as left bundle branch
block, left ventricular hypertrophy, or an artificial pacemaker device,
rendering ST-segment interpretation unreliable, were also excluded.
After enrollment, patients received a minimal daily dose of 50 mg
aspirin. In patients who were not taking aspirin at the time of
enrollment, the first dose was a minimum of 250 mg. Heparin was
administered before randomization until at least 1 hour after PTCA
and adjusted to an activated partial thromboplastin time between 2.0
and 2.5 times normal. All patients received intravenous nitroglycer-
in. b-Blockers, calcium channel blockers, and other cardiovascular
drugs were allowed (Table 1). In addition, patients received an
abciximab 0.25 mg/kg bolus followed by a continuous infusion of 10
mg/min or matching placebo for 18 to 24 hours preceding PTCA and
continuing for 1 hour after completion of the procedure.
During the hospital stay and 30-day follow-up, all events and
medication were recorded, with special attention to recurrent ische-
mic symptoms.
Study End Points
The incidence and severity of recurrent ischemia were described in
different parameters: the number of patients with recurrent ischemia,
the number of ischemic episodes in patients with recurrent ischemia,
and total ischemic burden across the placebo and abciximab patient
groups.
As in the main study, MI during the index hospitalization was
defined by CK-MB or CK levels exceeding 3 times the upper limit
of normal in 2 samples and increased by 50% over the previous
value, or an ECG with new significant Q waves in 2 or more
contiguous leads. MI after discharge was defined by CK-MB or CK
levels exceeding 2 times the upper limit of normal, or new significant
Q waves in $2 contiguous ECG leads.
Continuous ST-Segment Monitoring
Continuous ECG monitoring was started preferably before but not
later than 1 hour after enrollment. It was continued for at least 24 to
36 hours, including 6 hours after the PTCA procedure. The timing of
the start of drug infusion and the moments of angiography and PTCA
were obtained from the study case record forms.
Continuous ECG monitoring was performed using the MIDA
1000 vector-cardiographic ECG monitoring device (Ortivus Medi-
cal). This system calculates averaged QRS-T complexes from the
Frank orthogonal X-Y-Z leads at 1-minute intervals. These averaged
complexes were stored on hard disk and used for calculation of ST
trend information. After completion of the monitoring period, the
averaged ECG data were stored on a floppy diskette and sent to the
core laboratory at Cardialysis in Rotterdam, The Netherlands, for
subsequent editing and analysis.4,7
Editing and Analysis of ECG Data
All averaged X-Y-Z complexes were manually scanned and edited
for artifacts, intermittent bundle-branch block, detection or marker
errors, and postural changes. Postural changes were defined as a
sudden change of the electrical axis or a sudden QRS amplitude shift.
After editing, averaged 12-lead ECG complexes and 12-lead ECG
trends were generated from the MIDA X-Y-Z leads, using the
transformation formulas of Dower.13 Trends of the ST-segment level
measured at J point 1 60 ms were generated for each single lead of
this derived 12-lead ECG, except aVR.
Definition of ST Episodes
The onset of an ST episode was defined as a change in ST amplitude
of at least 6100 mV from the baseline ST level in $1 of the 12
derived leads, developing within a 10-minute period and persisting
for $1 minute. The end of an episode was defined as a return of the
ST level within 6100 mV of the baseline ST level, again lasting for
at least 1 minute. Episodes had to be separated from each other by
$1 minute.
If $100 mV ST change was present in .1 lead simultaneously,
the episode onset was defined by the lead exhibiting the first ST
change $100 mV. Similarly, the end of an episode was defined by
the lead exhibiting the latest return to baseline ST level. If chest pain
was present during or within 15 minutes before or after a an ST
episode, this ST episode was classified as symptomatic. An example
of the ST trend analysis and representative ECG recordings is
presented in Figures 1 and 2. An algorithm programmed according to
these ST criteria for ischemia, was used for detection of ST episodes,
with visual confirmation afterward. The ECG at moments of interest,
either detected by the algorithm or by the operator, was documented
on hard copy for visual inspection (Figure 2). An extensive report on
the method of editing and analysis of ECG data developed and used
by our core laboratory has been published recently.4
Ischemic Burden
Ischemic burden was calculated in 4 different ways: (1) as the sum
of the duration of all episodes per patient; (2) as the sum of the area
under the curve of the ST vector magnitude trend of all episodes per
patient (Figure 3); (3) as the sum of the area under the ST trend curve
of all leads involved in the ST episodes per patient; and (4) as the
sum of the area under the ST trend curve of all 12 leads during ST
episodes per patient (except aVR).
Statistical Analysis
Continuous variables are expressed as median and interquartile range
(25th and 75th percentiles) and compared using the Mann-Whitney
test. Discrete variables are described with percentages and were
compared using Fisher’s exact test. A two 2-tailed P value of #0.05
was considered statistically significant. The Kaplan-Meier method
was used for evaluation of the time to a recurrent ST episode and of
the time to the next ST episode, with censoring of data. Statistical
difference was tested with the log rank test. Relative risks are given
as univariate variables with 95% CIs.
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Results
In the CAPTURE study, a total of 1265 patients were
included at 69 sites in 12 countries.10 Three-hundred ninety-
four patients were also enrolled in the ECG-ischemia moni-
toring substudy. Of these 394 patients, 62 (16%) were
excluded from ECG analysis: 38 patients because of a late
start of the ECG monitoring (.1 hour after the start of drug
infusion or ,50% analyzable ECG data), 22 patients because
of technical failures due to errors on the part of the investi-
gator, and 2 patients because of a time mismatch of monitor-
ing data and the case record form. Thus, 332 patients (84%)
had ECG recordings suitable for final analysis. Most patients
(67%) experienced their ischemic episode qualifying for
study entry within 12 hours before the start of the study drug,
and 39% of the patients had their qualifying episode within 6
hours before enrollment. The majority of patients (193; 58%)
had either ST-segment depression or elevation or both of
$0.1 mV on their 12-lead ECG during the ischemic event,
which qualified them for inclusion into the study. Seventy-
five patients (23%) had T -wave changes only; and in 64
patients (19%), the entry ECG did not exhibit any ischemic
abnormality, although ST-segment changes had been rec-
orded during previous ischemic episodes.
CAPTURE Main Study Versus ECG-Ischemia
Monitoring Substudy
Of the 332 patients suitable for ST analysis, 163 patients
received placebo and 169 patients abciximab. Baseline data
were well balanced among the 2 treatment groups and
representative of the baseline data of the CAPTURE main
study (Table 1). Death or MI within 5 days occurred in 17
(10.4%) of the placebo patients and 4 (2.4%) of the abciximab
patients in the ECG-ischemia monitoring patient group
(P50.006) versus 40 (9.2%) and 23 (5.3%) of the patients
TABLE 1. Baseline Data and Concomitant Medication
ECG-Ischemia Monitoring Substudy
Main Study Patients
Not Included in
Substudy
Placebo (n5163) Abciximab (n5169) All (n5933)
No. of males, (%) 111 (68.1) 107 (63.3) 702 (75.2)
Mean age, y, (SD) 62 (10) 60 (10) 61 (10)
Anthropometry, mean (SD)
Weight, kg 77 (13) 77 (13) 75 (12)
Height, cm 172 (10) 171 (9) 169 (9)
Patients with, n (%)
Angina .7 days previously 90 (56.3) 89 (54.6) 443 (48.2)
Infarction within previous 7 days 16 (9.8) 19 (11.2) 131 (14.0)
Infarction 8–30 days 6 (3.7) 9 (5.3) 81 (8.7)
Infarction .30 days previously 33 (20.2) 33 (19.5) 153 (16.4)
PTCA 24 (14.7) 25 (14.8) 121 (13.0)
CABG 8 (4.9) 3 (1.8) 21 (2.3)
Risk factors, n (%)
Diabetes 17 (10.5) 19 (11.2) 141 (15.1)
Hypertension 58 (35.8) 65 (38.9) 409 (44.2)
Current smokers 71 (44.4) 66 (39.1) 353 (38.3)
Medication within 7 days before
enrollment, n (%)
Aspirin 143 (89.4) 149 (90.3) 865 (94.2)
Intravenous heparin 162 (99.4) 169 (100) 930 (99.7)
Nitrates 163 (100) 169 (100) 930 (99.9)
b-Blockers 116 (72.5) 125 (75.8) 583 (63.5)
Calcium antagonists 86 (53.8) 82 (49.7) 445 (48.5)
Medication after enrollment, n (%)
Aspirin 158 (96.9) 164 (97.0) 890 (96.2)
Ticlopidine 4 (2.5) 3 (1.8) 43 (4.6)
Intravenous heparin 158 (100) 160 (100) 909 (100)
Nitrates 160 (98.2) 166 (98.2) 903 (97.6)
b-Blockers 118 (72.4) 122 (72.2) 567 (61.3)
Calcium antagonists 84 (51.5) 86 (50.9) 438 (47.4)
Percentages were calculated only for those patients for whom data was reported.
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receiving abciximab or placebo, respectively, who were not
included in the ECG-ischemia monitoring substudy
(P50.04).
ECG-Ischemia Monitoring Substudy
The duration of the ECG monitoring periods before and after
the PTCA procedure did not differ among treatment groups
(Table 2).
Recurrent ischemia was detected in 31 (18%) of the 169
abciximab and in 37 (23%) of the 163 placebo patients. This
difference was not statistically significant (P50.34, Figure
4A). Yet, repetitive ischemia and total ischemic burden were
significantly decreased in patients receiving abciximab, both
for the period preceding the PTCA procedure and for the
complete monitoring period (Table 3). Excluding the time
period of the PTCA and the stay at the catheterization
laboratory, only 9 (5%) of abciximab versus 22 (14%) of
placebo patients had $2 ST episodes (P50.01); only 5 (3%)
of abciximab versus 15 (9%) of placebo patients had $3 ST
episodes (P50.02). Symptomatic episodes occurred in 5
(3%) of abciximab and 13 (8%) of placebo patients (P50.05).
These treatment effects were also apparent in the subgroup of
136 patients who exhibited ST-segment depression of $0.1
mV on their 12-lead ECG during the ischemic event that
qualified them for entry into the study. These patients had
more ischemic episodes than patients without ST-segment
depression at study entry (P50.055). In this subgroup, only 1
(2%) abciximab versus 9 (12%) placebo patients had $3 or
more ST episodes (P50.02). Total ischemic burden parame-
ters (as defined by the duration of ischemia per patient, the
sum of the area under the curve of the ST vector magnitude
during ST episodes, the sum of the area under the ST trend
Figure 1. Example of the vector-derived 12-lead
ST analysis of a study patient with unstable
angina who had an MI as a complication of a
PTCA procedure. The ST trends of the relevant
leads in which ST episodes occurred and the MI
developed are displayed. The black bars in each
single-lead ST trend represent the time during
which the algorithm detected an ST change
$100 mV. Note that the number and duration of
ST episodes differs across leads. At the bottom
of the trend graphs, the black bars indicate the
total duration and number of the ST episodes
(ischemia), taking into account all leads involved.
Before PTCA, 3 ischemic episodes occur around
17:30 and 18:00 hours. During angiography and
PTCA, possibly at the moment of first injection of
contrast, a sudden, severe ST-segment elevation
developed in leads II and III with simultaneous
ST-segment depression in lead V5. Subse-
quently, this ischemic event partially resolved,
followed by 2 short peaks of ST-segment eleva-
tion/depression, which reflect the inflations of the
balloon catheter. After the PTCA procedure, a persistent elevation of the ST segment is observed with depression in lead V5, suggest-
ing a persistent occlusion leading to acute MI. MI in this patient was confirmed by a rise of CK and CK-MB to 4 and 3 times, respec-
tively, the upper limit of normal and the development of Q waves. See also Figure 2.
Figure 2. Samples of the computer assisted
12-lead ECG recording of the patient in Figure 1.
A, Ischemic episode before PTCA, detected by the
algorithm. The upper ECG row (17:26 hours) dem-
onstrates the baseline “nonischemic” 12-lead ECG
(except aVR). The ECG rows directly below dem-
onstrate the time (17:34 hours) and ECG lead (indi-
cated in bold) in which the ST episode occurred.
ST changes are present in multiple leads, but the
first ST change is detected in lead II. However, the
maximum (MAX.) and ending of the episode are
detected in lead III (17:46). B, ECG sample during
PTCA. Note the severe ST-segment elevations in
the inferior leads with simultaneous ST-segment
depressions in leads V3 to V6. C, After PTCA,
ST-segment elevations persist in the same area as
during the procedure, suggesting an acute MI. As
the ST measurements during the PTCA procedure
were not included in the analysis, the algorithm
used the last ECG template before PTCA as the
reference “nonischemic” ECG (18:59). As such, the
onset of ischemia is again detected directly after
the procedure (20:01).
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curve of all leads involved, or the sum of the area under the
curve of all 12 leads during ST episodes) were reduced in
favor of abciximab (Table 3). Thus, patients receiving abcix-
imab had significantly less frequent and fewer severe ische-
mic episodes. Both the probabilities to remain free from a
second ischemic episode after the start of monitoring and to
remain free from a second ischemic episode after the first
were significantly higher for patients receiving abciximab
(P50.01 and 0.02, respectively, Figure 4B and 4C).
The majority of clinical events occurred during and within
24 hours after PTCA. Eighteen patients had an MI, and 3 died
within 5 days of treatment. Eventually, 24 patients developed
MI or died within 30 days of follow-up (7.2%). The presence
of chest pain without concomitant ST episodes during the
monitoring period preceding the PTCA procedure was not
related to an increased relative risk of subsequent events.
However, the presence of any ST episode and especially of
any symptomatic ST episode was associated with an in-
creased relative risk of 3.2 (95% CI 1.4, 7.4; absolute risk
15%) and 4.1 (95% CI 1.4, 12.2; absolute risk 23%),
respectively. This association also remained apparent for the
occurrence of MI or death within 30 days.
Discussion
In the CAPTURE study, treatment with abciximab (c7E3 Fab,
ReoPro) resulted in a 50% reduction in MI and 29% reduction in
the primary composite end point of death, MI, or urgent
(re)intervention in patients with refractory unstable angina.10 The
results of the present ECG-ischemia monitoring substudy, which
included 332 of the 1264 patients of CAPTURE are consistent
with these findings. Compared with placebo, treatment with
abciximab resulted in a greater reduction of frequent ischemia
and symptomatic ischemic episodes during continuous ECG-is-
chemia monitoring; it also resulted in a major reduction of
ischemic burden in patients with ischemia. This extends the
observation in CAPTURE that treatment with abciximab re-
duced the occurrence of MI during the 16- to 24-hour period of
treatment before PTCA was performed. It is likely that the
reduction of recurrent ischemia reflected stabilization of the
plaque, resolution of thrombus, and prevention of recurrent
thrombosis by abciximab, which led to the reduction of clinical
events. This is supported by the observation that the presence of
recurrent ischemia during the ST monitoring period before
PTCA appeared strongly predictive of MI and death within the
next 5 days; this is in concordance with previous studies using
Holter ST monitoring, demonstrating that ischemic ST episodes
relate to clinical outcome in patients with unstable angina.14–17
Our study demonstrates that ischemia, detected during
vector-derived multilead ECG-ischemia monitoring, can be
used as a study end point in patients with unstable coronary
syndromes. The prevalence of ischemia using Holter ST
monitoring or continuous ECG-ischemia monitoring tech-
niques in patients with unstable angina has been reported as
50% to 70%.4,14–17 This is in contrast to the lower percentage
of patients (21%) exhibiting ischemia in the present study. It
may be explained by the intensive therapy of these patients
before enrollment in CAPTURE, which included aspirin,
heparin, nitroglycerin, and b-blockers in most patients. It
TABLE 2. Duration of ST Monitoring Periods
Placebo Abciximab All Patients
Patients, n 163 169 332
Total monitoring time, h* 28 (26, 29) 27 (26, 29) 28 (26, 29)
Duration of stay at cath-lab, h* 1.3 (1.0, 1.7) 1.3 (1.0, 1.7) 1.3 (1.0, 1.7)
Total analyzable monitoring time, h* 27 (24, 28) 26 (25, 28) 26 (25, 28)
Start study until PTCA, h* 20 (18, 21) 19 (18, 21) 20 (18, 21)
End PTCA until end monitoring, h* 6 (6, 7) 6 (6, 7) 6 (6, 7)
ECG data loss, %* 2 (1, 7) 2 (1, 5) 2 (1, 6)
*Median (25th, 75th percentiles).
Figure 3. Measurement of the ischemic burden.
For simplification, only a magnification of the ST
trend of a single lead is displayed. Three ST epi-
sodes $100 mV are detected between 07:10 and
07:50 hours. The ST-segment elevations around
08:00 and 08:50 hours do not reach the threshold
of 100 mV and are not classified as ST episodes.
The area under the trend curve of the episodes is
measured from the baseline ST level that is pres-
ent at the moment of the beginning of the epi-
sode. These ST measurements are repeated for all
12 leads except aVR. Subsequently these values
are summated, thus reflecting the total area under
the curve for all leads involved. The same proce-
dure is followed for the ST vector magnitude, but
in this case the onset and ending of episodes
remain defined by the ST onset and ending
measurements taken from the vector-derived
12-lead ECG.
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suggests that some of these patients may already have been
stabilized by this intensive therapy.
In patients without recurrent ischemia, as in patients
without elevated troponin T levels,18–20 the risk of MI and
death is low, particularly when treated with a glycoprotein
IIb/IIIa receptor blocker. Thus it may be questioned whether
early PTCA is necessary. In patients who appear to have been
stabilized through medical therapy (eg, abciximab), a PTCA
procedure could possibly be deferred to a later time to allow
further stabilization of the unstable plaque. On the other hand,
patients with recurrent ischemia during ECG monitoring (as
well as patients with elevated troponin T levels) exhibited a
higher risk of MI or death.20 This suggests that those patients
who remain unstable will benefit from immediate or urgent
invasive therapy and may benefit from treatment with abcix-
imab both before and during PTCA. If urgent intervention is
not possible, these patients should be stabilized with a platelet
glycoprotein IIb/IIIa receptor blocker.
Conclusions
The present ECG-ischemia monitoring study, which was
conducted as a substudy of CAPTURE,10 demonstrates that
treatment with abciximab versus placebo is associated with
a reduction of frequent ischemia and a reduction of total
ischemic burden in patients with refractory unstable angina
both before (thus stabilizing patients) and after PTCA. The
incidence of recurrent ischemia appeared lower than ob-
served in patients with unstable angina studied shortly
after hospital admission.4,14 –17 This indicates that, most
patients tend to stabilize over time, particularly when
treated with abciximab.
The presence of recurrent ischemia predicts MI or death
both within 5 days’ and at 30 days’ follow-up. As such,
continuous vector-derived 12-lead ECG monitoring appears
to be a useful noninvasive tool for further risk stratification
and selection of high risk unstable patients who may require
invasive intervention and/or platelet glycoprotein IIb/IIIa
receptor blocker therapy.
Figure 4. Kaplan-Meier estimate of the
probability to remain free of an ST epi-
sode during the course of the monitoring
period. A, Probability to remain free from
a recurrent ST episode from the start of
medication. The continuous curve repre-
sents the patients treated with placebo
(163) and the dashed curve the patients
treated with abciximab (169). B, Proba-
bility to remain free from a second ST
episode from the start of medication. C,
Probability to remain free from a second
ST episode after the first one has ended.
The continuous curve represents the
patients with at least 1 ST episode
treated with placebo (37) and the dashed
curve the patients with at least 1 ST episode treated with abciximab (31). Both the probability to remain free from a second ischemic
episode after the start of medication and the probability to remain free from a second ischemic episode after the first one appear sig-
nificantly better for patients treated with abciximab.
TABLE 3. ST Monitoring Results
Period From Start of Study Until
Balloon Angioplasty
Period Following Balloon
Angioplasty Total Monitoring Period
Placebo Abciximab P Placebo Abciximab P Placebo Abciximab P
Patients, n 163 169 155 162 163 169
ST-episodes, n (%)
$1 29 (18) 24 (14) NS 16 (10) 9 (6) NS 37 (23) 31 (18) NS
$2 18 (11) 9 (5) 0.07 15 (10) 8 (5) NS 22 (14) 9 (5) 0.01
$3 12 (7) 3 (2) 0.02 2 (1) 0 (0) NS 15 (9) 5 (3) 0.02
Symptomatic episodes 9 (6) 4 (2) NS 6 (4) 1 (1) 0.06 13 (8) 5 (3) 0.05
Ischemic burden*
Total duration per patient, min 12 6 NS 61 9 0.10 38 8 0.02
ST-VM, mV z min 1293 677 NS 7084 796 0.06 4819 796 0.01
12-lead ST area, mV z min 8832 4682 NS 45 599 3876 0.10 29 392 5376 0.01
ST area of leads $100 mV, mV z min 2394 1383 NS 27 026 1858 NS 8558 1858 0.03
The number of ST episodes were compared using Fisher’s exact test. Ischemic burden variables are given as medians and were compared using the Mann-Whitney
test. A 2-tailed P value of #0.05 was considered statistically significant. Borderline-significant P values #0.10 are also indicated.
*Patients with ischemia only. Total duration indicates the sum of the duration of all episodes per patient; ST-VM, the sum of the area under the curve of the ST
vector magnitude trend of all ST episodes per patient; 12-lead ST-area, the sum of the area under the ST trend curve of all 12 leads during ST episodes per patient
(except a VR); and ST area of leads $100 mV, the sum of the area under the ST trend curve of all leads involved in the ST episodes per patient (except a VR).
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